68Ga-NODAGA-THERANOST

68Ga-NODAGA-THERANOST is a radiolabeled peptidomimetic that acts as an αvβ3 integrin antagonist. It is the first compound of its kind to reach clinical development for targeting integrin receptors, specifically for imaging tumor angiogenesis using positron emission tomography/computed tomography (PET/CT). The drug demonstrates high specificity and sensitivity in detecting tumors and metastatic sites, with rapid blood clearance, stability, and rapid renal excretion. Its primary use has been in the diagnosis of cancers such as non-small-cell lung cancer and breast cancer by visualizing neoangiogenesis. The agent may also enable theranostic approaches—combining diagnostics with targeted antiangiogenic therapy or image-guided interventions—and supports personalized medicine strategies[2][5][6][7].

Other names

NODAGA-THERANOST GA-68